In a report released today, Patrick Wood from Morgan Stanley maintained a Buy rating on Intuitive Surgical (ISRG – Research Report), with a price target of $650.00.
Patrick Wood’s rating is based on several compelling factors that highlight the potential growth and value of Intuitive Surgical’s stock. The recent datasets collected from industry conferences, particularly SAGES 2025, have reinforced confidence in the adoption of the Dv5 system and its ability to reduce costs closer to traditional laparoscopic procedures. This suggests a positive outlook for the company’s technological advancements and market penetration.
Moreover, the growth in Intuitive Surgical’s general surgery segment is more evenly distributed across different procedures than initially expected. While cholecystectomy has been a significant contributor, accounting for about 25% of growth, inguinal hernia and ventral hernia have shown even greater contributions. This diversified growth, coupled with the recent stock pullback, presents an attractive entry point for investors, supporting the Buy rating for ISRG.
Wood covers the Healthcare sector, focusing on stocks such as Intuitive Surgical, Boston Scientific, and Stryker. According to TipRanks, Wood has an average return of 1.2% and a 50.59% success rate on recommended stocks.
In another report released on March 21, Truist Financial also maintained a Buy rating on the stock with a $605.00 price target.